Manuel López-Figueroa, PhD, is a Managing Director at Bay City Capital and has been with the firm since 2001. Bay City Capital is one of the world’s premier life science investment firms investing in over 100 companies and with more than $1.6 billion under management. In addition, Dr López-Figueroa is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, which is comprised of leaders in psychiatry, neuroscience, and genetics from Stanford University, University of Michigan, Cornell University, the University of California at Irvine, and the HudsonAlpha Institute for Biotechnology.
Dr López-Figueroa has over 25 years of experience in the field of neuroscience, has won numerous awards during his academic career and has published extensively. Dr. López-Figueroa has a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark.
Dr. López-Figueroa serves on the boards of Orfan Biotech (BridgeBio’s Pharma subsidiary), IMIDomics and Zulia Biotech. He is an investment advisor to Nina Capital and Global Neurohealth Ventures.
First appointment as Director: 11 may 2020
Re-election: 02 september 2020
Company shares: CNMV